TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of written informed consent.~2. Men, over 18 years of age, with histologically-confirmed diagnosis of prostate cancer~3. History of treatment by complete androgen blockade for greater than 3 months prior to enrollment~4. Progressive disease evidenced by 2 consecutive rises in PSA measured at least 1 week apart, with the absolute value of the latest PSA \> 5.0 ng/ml.~5. A rise in PSA following anti-androgen drug withdrawal, above the last PSA value before withdrawal.~6. Patient has agreed to treatment for hormone-refractory (ie. castrate-resistant) prostate cancer under supervision of a medical oncologist, urologist, radiation oncologist or nuclear medicine physician. Treatments indicated for HRPC are docetaxel-, cabazitaxel-, or mitoxantrone-based chemotherapy, abiraterone, radium-223, enzalutamide, or sipulecuil-T.~Exclusion Criteria:~1. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or superficial transitional cell carcinoma of the bladder.~2. Serious underlying medical conditions that would otherwise impair the patient's ability to undergo imaging.~3. Patient weighs over 350 lbs (due to scanner weight limit).~4. Clinical life expectancy \< 12 weeks.~5. Participated in other radioactive drug studies where estimated total cumulative dose within 1 year is \> 0.05 Sievert for whole body, active blood-forming organs, eye lens, gonads, or 0.15 Sievert for other organs.~6. Concurrent Therapy. Allowed: Prior or concurrent chemotherapy, but must be \> 12 weeks since last treatment at enrollment; prior or concurrent hormonal therapy; prior surgery; prior or concurrent bisphosphonate; prior or concurrent receptor/biologic agent allowed if given on approved study protocol.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Received 18F-fluorocholine PET/CT (Type: EXPERIMENTAL): IV fluorine-18 labeled methylcholine before PET/CT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LASIK Flap Thickness and Visual Outcomes Using the WaveLight FS200 Femtosecond Laser

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with ametropia (Spherical, spherocylindrical, presbyopic) suitable for treatment by LASIK, including different target refractions (Plano or Monovision).~Exclusion Criteria:~* Patients unsuitable for LASIK procedure because of an estimated residual stromal bed \< 300 microns after calculation of the ablation (Corneal thickness - flap thickness - simulated stromal ablation for the desired correction).~* Patients unsuitable for LASIK due suspicious topography for ectasia, form frust keratoconus or unstable ( more than 0.50 diopter change in sphere or cylinder in the last year) refraction.~* Patients with amblyopia or any eye disease that might limit the visual recovery.~* Patients younger than 18 years old.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FS200 femtosecond laser LASIK (Type: EXPERIMENTAL): LASIK flap created with an FS200 femtosecond laser system
- IntraLase femtosecond laser LASIK (Type: EXPERIMENTAL): LASIK flap created with an IntraLase femtosecond laser system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed invasive carcinoma of the breast for which adjuvant systemic therapy is appropriate~  * Stage I, II, or IIIA~ * Pathologically positive or negative nodes~ * Any size primary tumor~* No edema, peau d'orange, infiltration of the skin, or direct extension to the chest wall~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* Not specified~Sex:~* Female~Menopausal status:~* Pre-, peri-, or postmenopausal~Performance status:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* No prior malignancy except:~  * Basal cell carcinoma~ * Carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~Chemotherapy:~* See Disease Characteristics~Endocrine therapy:~* See Disease Characteristics~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* No prior systemic treatment for breast cancer

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who completed the treatment period of Study LG-ECCL002~* Patients requiring continuous treatment for rheumatoid arthritis upon the investigator's discretion~* For childbearing female patients or surgically non-sterile male patients, those who agreed to avoid pregnancy using proper contraceptive methods during the study.~* Patients who made a voluntary decision to participate in this clinical study and gave a voluntary written consent to comply with all the instructions with full understanding after being informed of the study~Exclusion Criteria:~* Patients deemed difficult to participate in this extension study due to the adverse events which occurred in Study LG-ECCL002, upon the investigator's discretion at screening~* Patients with at least 10 swollen joints (out of the total 66 assessing joints) or at least 12 tender joints (out of the total 68 assessing joints) at screening~* Women in pregnancy or lactation, or patients planning to be pregnant during the study period~* Patients ineligible for this clinical study upon the investigator's discretion

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LBEC0101 (Type: EXPERIMENTAL): Etanercept 50mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients clinically diagnosed with treatment-resistant schizophrenia (TRS) (TRRIP consensus criteria).~* Patients aged 18-60 years of either sex.~* Patients giving voluntary written consent for participation in the study~Exclusion Criteria:~* Patient already on Clozapine or ECT.~* History of psychoactive substance abuse or dependence.~* Co-morbid psychiatric, major medical, or neurological disorders.~* History of organicity or significant head injury.~* Pacemaker or metal in any part of the body excluding the mouth.~* Pregnant and breastfeeding females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Test group (Type: EXPERIMENTAL): Bilateral Maintenance ECT (B/L M-ECT)
- Control group (Type: ACTIVE_COMPARATOR): Clozapine monotherapy. Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Papillary Serous Carcinoma of the Endometrium

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient must undergo surgical staging within 8 weeks of study entry.~2. Patients with mixed histology tumor that include a papillary serous component are eligible.~3. Only patients with non-measurable disease can be entered.~4. Patients may not have had previous chemotherapy or radiation therapy.~5. Patients must have an estimated life expectancy of 12 weeks or greater.~6. Patients must have a Zubrod performance status of less than or equal to 2.~7. Patients must have adequate bone marrow, renal and hepatic function: with white blood count (WBC) greater than or equal to 3000; Absolute neutrophil count (ANC) greater than or equal to 1500; Platelets greater than or equal to 100,000; glutamic-pyruvic transaminase (SGPT) less than or equal to 2 times the upper limit of normal; Total bilirubin less than or equal to 2.5mg/dl.~8. Patients must sign an institutionally approved consent form~Exclusion Criteria:~1. Previously treated papillary serous carcinoma with either chemotherapy or radiation therapy.~2. Newly diagnosed papillary serous carcinoma of the endometrium, Stage IIIB-IV (patients with disease outside the pelvis).~3. Patients who have a history of other malignancy, with the exception of non-melanomatous skin cancer, unless in complete remission and off all therapy for that disease for a minimum of 5 years.~4. Patients with a Zubrod status of 3 or greater.~5. Patients with an active infection.~6. Patients with serious intercurrent medical illness.~7. Patients with a recent (within 6 months) history of congestive heart failure, unstable angina or myocardial infarction.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel (Taxol) + Pelvic Radiation (Type: EXPERIMENTAL): Paclitaxel (Taxol) 50 mg/m\^2 intravenous (IV) weekly over 1 hour for 5 weeks. Radiation therapy to the pelvis daily for 25 treatments.~Both radiation therapy and paclitaxel chemotherapy on Day 1 or 2, followed by radiation alone for four days, repeated every week for a total of 5 weeks, giving a total dose of 45 Gy with external beam radiation to pelvis and 5 courses of paclitaxel 50 mg/m\^2. Four-six weeks after pelvic radiation completed, 4 additional courses of paclitaxel 135 mg/m\^2 alone given every 21 days. Vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for additional 3 days. No chemotherapy given with vaginal apex boost.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>/=18 years of age~* early rheumatoid arthritis (disease symptoms \<1 year) according to ACR criteria~* disease activity DAS28 \>2.6~* body weight \</=110kg, BMI \</=36~Exclusion Criteria:~* rheumatic autoimmune disease other than RA~* current inflammatory joint disease other than RA~* previous treatment with any DMARD or biologic drug used in the treatment of RA~* intra-articular, parenteral or oral glucocorticoids used for the arthritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab + Methotrexate (Type: EXPERIMENTAL): Participants will receive intravenous (IV) TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + oral capsules of MTX 10-30 mg/week in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week. The weekly dose of MTX will be taken on one particular day of the week.
- Tocilizumab + Placebo Methotrexate (Type: ACTIVE_COMPARATOR): Participants will receive IV TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + weekly oral matching placebo MTX capsules in climbing dosages. The weekly dose of placebo MTX will be taken on one particular day of the week.
- Methotrexate + Placebo Tocilizumab (Type: ACTIVE_COMPARATOR): Participants will receive weekly oral MTX in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week + matching placebo TCZ IV 8 mg/kg every four week for a maximum of 26 infusions. The weekly dose of MTX will be taken on one particular day of the week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Genetically confirmed CDKL5 gene mutation, seizure onset by 1 year of age and lack of independent ambulation by 2 years of age~* Failure to control seizures despite 2 or more anti-seizure medications~* At least 16 seizures per 28 days of primary seizure types~* On a stable regimen of 0-4 anti-seizure medications (Vagus nerve stimulator, ketogenic diet, and modified Atkins diet do not count towards this limit)~* Additional Inclusion Criteria apply and can be discussed with study team~Exclusion Criteria:~* Previous exposure to ganaxolone~* West Syndrome with hypsarrhythmia pattern on EEG or seizures predominantly of Infantile Spasms type~* Use of adrenocorticotropic hormone (ACTH), prednisone or other glucocorticoid or use of moderate or strong inducers or inhibitors of CYP3A4/5/7 are prohibited~* Use of tetrahydrocannabinol (THC) or cannabidiol (CBD) is prohibited during the double-blind phase, unless patient has a prescription of Epidiolex®~* Exposure to any other investigational drug within 30 days or fewer than 5 half-lives prior to screening~* Plasma allopregnanolone-sulfate (Allo-S) levels greater than or equal to 6.0 ng/ml at screening visit~* Additional Exclusion Criteria apply and can be discussed with study team

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Ganaxolone (Type: EXPERIMENTAL): ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
- Placebo (Type: PLACEBO_COMPARATOR): placebo suspension 3x's /day for 17 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Isoenergetic High Intensity Interval Training and Moderate Intensity Training in Adults With Type I Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of presumed autoimmune T1D, receiving daily insulin~* Last hemoglobin A1c \<9%~* 18-51 years~* Duration of T1D: ≥ 1 year~* Body mass index (BMI) \<30 kg/m\^2~* Generally healthy, with no conditions that could influence the outcome of the trial, and in the judgement of the investigators is a good candidate for the study, based on a review of health history~Exclusion Criteria:~* Physician diagnosis of active diabetic retinopathy that could be worsened by exercise~* Physician diagnosis of peripheral neuropathy with insensate feet~* Physician diagnosis of autonomic neuropathy~* Medications: beta-blockers, agents that affect hepatic glucose production such as beta adrenergic agonists, xanthine derivatives; any hypoglycemic agent other than insulin.~* Severe hypoglycemic event defined as the individual requiring a third party of hospitalization in the last 6 months~* Diabetic ketoacidosis in the last 6 months~* Has a closed-loop pump and not willing to use manual mode~* Physician diagnosis of cardiovascular disease that would affect exercise tolerance~* Currently doing HIIT~* Severely impaired hearing or speech~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 51 Years
- Healthy Volunteers: f

Study Arms:
- High intensity interval training, Moderate Intensity Continuous Training, Control (Type: EXPERIMENTAL): Participants randomly assigned to this arm will first receive high intensity interval training and then randomly assigned to both moderate intensity continuous training and control session, on different days.
- Moderate Intensity Continuous Training, High Intensity Training, Control (Type: EXPERIMENTAL): Participants randomly assigned to this arm will first receive moderate intensity continuous training then randomly assigned to both high intensity interval training and a control session, on different days.
- Control session, High intensity interval training, moderate intensity continuous training (Type: EXPERIMENTAL): Participants randomly assigned to this arm will first complete a control session (no exercise) and then randomly assigned to both by a high intensity interval training and moderate intensity continuous training session, on different days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older;~* Pathological diagnosis of patients with stage II, III A primary NSCLC;~* R0 resection has been accepted;~* Received adjuvant chemotherapy or adjuvant chemotherapy for the first time after surgery;~* Informed consent has been signed.~Exclusion Criteria:~* Incorporation of other malignant tumors (such as leukemia, liver cancer, etc.);~* Patients with unclear pathological types;~* Patients with unclear pathological staging;~* Preserved Shenlingcao Oral Liquid before R0 resection surgery;~* Received immunotherapy or targeted therapy before R0 resection surgery;~* Radiotherapy and chemotherapy before R0 resection surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
- Control group (Type: NO_INTERVENTION): Patients receive conventional adjuvant chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with T2DM with inadequate glycemic control on metformin monotherapy or on metformin in combination with an SU at protocol-specified doses and having HbA1c \>=7.0% and \<=10.5% at Week -2 are eligible for enrollment in the study.~Exclusion Criteria:~* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy~* Has repeated (ie, 2 or more over a 1-week period) fasting plasma glucose (FPG) and/or fasting self-monitored blood glucose (SMBG) measurements \>=270 mg/dL (15 mmol/L) during the pre-treatment phase, despite reinforcement of diet and exercise counseling~* History of a severe hypoglycemic episode within 6 months before screening~* History of or current illness considered to be clinically significant by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 100mg (Type: EXPERIMENTAL): Each participant will receive 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
- Canagliflozin 300mg (Type: EXPERIMENTAL): Each participant will receive 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
- Placebo (Type: PLACEBO_COMPARATOR): Each participant will receive matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete